At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 196 enrolled
Drug / intervention
Placebo +3 moredrug
Likely dose
Placebo 0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 2 or 3 Infection
In Brief
A Phase 2 clinical trial evaluating Placebo, Daclatasvir, and 2 other interventions for Hepatitis C Virus. Completed, enrolled 196 participants across 26 sites in 6 countries.
Detailed Summary
To identify a shorter duration of antiviral therapy (12 or 16 weeks) for the combination of daclatasvir with pegylated interferon alfa-2a and ribavirin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus
CountriesAustralia, Canada, Denmark, France, Italy, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedDec 2010
Primary CompletionMay 2012
Study CompletionSep 2012
TodayJul 2026
First PostedDec 9, 2010
Enrollment StartDec 1, 2010
Primary CompletionMay 1, 2012
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.6 years ago
Interventions
Placebodrug
Tablets, oral, 0 mg, once daily, for 24 weeks
Daclatasvirdrug
Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
Pegylated interferon alfa-2adrug
Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
Ribavirindrug
Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks